Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study

Autor: Carmen Escuriola Ettingshausen, Vladimír Vdovin, Nadezhda Zozulya, Pavel Svirin, Tatiana Andreeva, Majda Benedik-Dolničar, Victor Jiménez-Yuste, Lidija Kitanovski, Silva Zupancic-Šalek, Anna Pavlova, Angelika Bátorová, Cesar Montaño Mejía, Gulnara Abdilova, Sigurd Knaub, Martina Jansen, Shannely Lowndes, Larisa Belyanskaya, Olaf Walter, Johannes Oldenburg

Publikováno v: TH Open, Vol 06, Iss 02, Pp e124-e134 (2022)

Background Immune tolerance induction (ITI) with repeated factor VIII (FVIII) administration is the only strategy proven to eradicate inhibitors. The observational ITI study is evaluating ITI with a range of FVIII products. Methods This subgroup anal

Externí odkaz: https://doaj.org/article/a52b126df9af4fd18ab2a85705afdb71

Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study

Autor: Carmen, Escuriola Ettingshausen, Vladimír, Vdovin, Nadezhda, Zozulya, Pavel, Svirin, Tatiana, Andreeva, Majda, Benedik-Dolničar, Victor, Jiménez-Yuste, Lidija, Kitanovski, Silva, Zupancic-Šalek, Anna, Pavlova, Angelika, Bátorová, Cesar, Montaño Mejía, Gulnara, Abdilova, Sigurd, Knaub, Martina, Jansen, Shannely, Lowndes, Larisa, Belyanskaya, Olaf, Walter, Johannes, Oldenburg

Publikováno v: TH open : companion journal to thrombosis and haemostasis. 6(2)

Background Immune tolerance induction (ITI) with repeated factor VIII (FVIII) administration is the only strategy proven to eradicate inhibitors. The observational ITI study is evaluating ITI with a range of FVIII products. Methods This subgroup anal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa2e258334b174cbbd5a342542bc6f59
https://pubmed.ncbi.nlm.nih.gov/35707623

Immunogenicity, efficacy and safety of Nuwiq®(human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study

Autor: John K. Wu, Leonid Dubey, R. Liesner, Michael Gattens, Larisa Belyanskaya, Marianne Sigaud, Olga Aleinikova, N. Kavardakova, Manuel Carcao, Carmen Altisent, Anthony K.C. Chan, Jonathan M. Ducore, Yves Gruel, Sigurd Knaub, M. Abashidze, N. A. Fouzia, Benoît Guillet, Hervé Chambost, M. Jansen, Thierry Lambert, Olaf Walter, M. El Khorassani, V. Turea, A. Borel-Derlon, Vladimir Vdovin, Sunil Lohade, Ellis J. Neufeld, Mark Belletrutti, A. Pavlova, Anna Klukowska

Publikováno v: Haemophilia. 24:211-220

Introduction Nuwiq® (Human-cl rhFVIII) is a fourth generation recombinant FVIII, produced in a human cell line, without chemical modification or protein fusion. No inhibitors developed in studies with Nuwiq® in 201 previously treated patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0f58013f2fc1d80d8e57f1609e5883d4
https://doi.org/10.1111/hae.13320

Estimation of Nuwiq ® (simoctocog alfa) activity using one‐stage and chromogenic assays—Results from an international comparative field study

Autor: Johanna A. Kremer Hovinga, Tiago Vicente, Guenther Kappert, Stefan Tiefenbacher, Manuela Albisetti, Peter Baker, Carin Borgvall, Catherine Ternisien, Olaf Walter, Larisa Belyanskaya, Ute Scholz, Claire Pouplard, Johannes Oldenburg, Steve Kitchen

Publikováno v: Tiefenbacher, Stefan; Albisetti, Manuela; Baker, Peter; Kappert, Guenther; Kitchen, Steve; Kremer Hovinga, Johanna A.; Pouplard, Claire; Scholz, Ute; Ternisien, Catherine; Borgvall, Carin; Vicente, Tiago; Belyanskaya, Larisa; Walter, Olaf; Oldenburg, Johannes (2019). Estimation of Nuwiq® (simoctocog alfa) activity using one-stage and chromogenic assays-Results from an international comparative field study. Haemophilia, 25(4), pp. 708-717. Wiley 10.1111/hae.13763
Haemophilia

BACKGROUND Accurate determination of coagulation factor VIII activity (FVIII:C) is essential for effective and safe FVIII replacement therapy. FVIII C can be measured by one-stage and chromogenic substrate assays (OSAs and CSAs, respectively); howeve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9ce45bc0bcad9fef20b2011538e3503
https://www.zora.uzh.ch/id/eprint/179542/

Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type

Autor: Ri Liesner, Joris Versteden, Shannely Lowndes, Johannes Oldenburg, Larisa Belyanskaya, Anna Pavlova

Publikováno v: Blood. 132:1204-1204

Background: The SIPPET study investigated inhibitor development in 251 previously untreated patients (PUPs) treated with either plasma-derived FVIII products containing von Willebrand factor (pdFVIII/VWF; n = 125), or recombinant FVIII (rFVIII; n = 1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::74654381833bb772937998034d6f76c2
https://doi.org/10.1182/blood-2018-99-110608